Eikon Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell

Eikon Therapeutics, Inc. (Nasdaq: EIKN), a California-based, late-stage biotechnology company, visits the Nasdaq MarketSite in Times Square. Eikon is led by executive and clinical teams behind the development and commercialization of some of most successful cancer drugs on the market today. Eikon integrates an advanced, proprietary engineering platform with cutting-edge molecular/cell biology to accelerate the discovery and development of new medicines for the millions of people impacted by cancer.

In honor of the occasion, Roger M. Perlmutter Chairman and CEO rings the Opening Bell.